Trial
NCT04371393
MSCs in COVID-19 ARDS
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Mesoblast, Inc.; National Heart, Lung, and Blood Institute (NHLBI)
Condition
Mesenchymal Stromal Cells
Intervention
Remestemcel-L
Why stopped
At 3d interim analysis, randomization, but not follow-up, was halted by the DSMB due to low predictive probability of achieving postulated mortality benefit (pre-specified 42.5% relative mortality reduction) were the trial to complete randomization.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-25